COMPLETE GENOMICS INC Form 8-K March 09, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 3, 2011

COMPLETE GENOMICS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

001-34939 (Commission 20-3226545 (IRS Employer

of incorporation) File Number) Identification Number)

2071 Stierlin Court

Mountain View, California 94043

(Address of principal executive offices, including Zip Code)

Registrant s telephone number, including area code: (650) 943-2800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On March 3, 2011, at a meeting of the Compensation Committee (the <u>Committee</u>) of the Board of Directors of Complete Genomics, Inc. (the <u>Company</u>), the Committee approved discretionary cash bonuses to certain of the Company s executive officers for 2010:

Executive Officer and Position]	Discretionary Bonus Amount	
Ajay Bansal, Chief Financial Officer	\$	70,000	
Bruce Martin, Senior Vice President of Product Development	\$	70,000	
Mark J. Sutherland, Senior Vice President of Business Development	\$	28,000	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 9, 2011 COMPLETE GENOMICS, INC.

By: /s/ Ajay Bansal Ajay Bansal

Chief Financial Officer